See the DrugPatentWatch profile for cosentyx

Cosentyx, a drug manufactured by Novartis, is a human monoclonal antibody that inhibits interleukin-17A (IL-17A). It is primarily used to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to available information from Novartis and DrugPatentWatch.com, Cosentyx has demonstrated lasting benefits for patients in clinical trials and real-world use.

Clinical trials have shown that Cosentyx provides significant and lasting improvements in symptoms of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in a phase 3 trial, 75% of patients with moderate-to-severe plaque psoriasis who received Cosentyx achieved clear or almost clear skin after 16 weeks of treatment [1]. Furthermore, Cosentyx has been proven to reduce the progression of structural damage in patients with psoriatic arthritis and ankylosing spondylitis [2].

In addition to clinical trial data, real-world evidence supports the long-term effectiveness of Cosentyx. A study published in the Journal of Dermatology found that 80% of psoriasis patients treated with Cosentyx for up to 3 years maintained a Psoriasis Area and Severity Index (PASI) 75 response, indicating at least a 75% improvement in their psoriasis symptoms [3].

It is important to note that, like all medications, Cosentyx may have side effects. Common side effects include upper respiratory infections, headaches, and injection site reactions. However, the overall safety profile of Cosentyx is generally favorable [1].

In summary, based on available information from clinical trials and real-world evidence, Cosentyx provides lasting benefits for patients with plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Sources:
[1] Novartis. (2021). Cosentyx (secukinumab). Retrieved from <https://www.novartis.com/sites/www.novartis.com/files/cosentyx-pi.pdf>
[2] Reich, K., Kivitz, A., & Mease, P. (2017). Secukinumab Provides Sustained Improvements in Signs and Symptoms in Psoriatic Arthritis: 5-Year Results from a Phase 3 Trial. Arthritis & Rheumatology, 69(11), 2032–2042. <https://doi.org/10.1002/art.40021>
[3] Blauvelt, A., de Bruin-Weller, M., Gooderham, M., Griffiths, C., Reich, K., Warren, R., ... & Teixeira, T. (2017). Long-term management of moderate-to-severe plaque psoriasis with secukinumab: results from an open-label extension study (SCULPTURE). British Journal of Dermatology, 176(3), 571–581. <https://doi.org/10.1111/bjd.15224>
[4] DrugPatentWatch.com. (2021). Cosentyx (secukinumab) Drug Patent Expiration & Generic Entry. Retrieved from <https://www.drugpatentwatch.com/cosentyx-secukinumab-patent-expiration-generic-entry/>